Kurume, Japan

Taimu Yamada

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Bonac Corporation, Other. Active years: 2020.

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:

goldMedal1 out of 19 
 
Bonac Corporation
 patents
silverMedal1 out of 834,411 
Other
 patents
where one patent can have more than one assignee

Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Taimu Yamada: Innovator in Nucleic Acid Technology

Introduction

Taimu Yamada is a notable inventor based in Kurume, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid compositions.

Latest Patents

Yamada holds a patent for a composition that stably contains a single-stranded nucleic acid molecule designed to suppress the expression of the TGF-β1 gene. The patent details a composition that includes a nucleotide sequence represented as 5'-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-P-G-3′ (SEQ ID NO: 1). This invention is significant for its potential applications in gene expression regulation.

Career Highlights

Throughout his career, Taimu Yamada has worked with Bonac Corporation, where he has contributed to various innovative projects. His work has focused on advancing the understanding and application of nucleic acid technologies.

Collaborations

Yamada has collaborated with notable colleagues, including Hidekazu Toyofuku and Kohei Tahara. These partnerships have fostered a collaborative environment that enhances research and development in their field.

Conclusion

Taimu Yamada's contributions to nucleic acid technology and his innovative patent highlight his role as a significant figure in biotechnology. His work continues to influence advancements in gene expression research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…